What is the company's primary source of revenue and how is it performing?

Regeneron's primary revenue source in this period comes from contract research and development, notably driven by the collaboration with Novartis for the IL-1 Trap. Total revenue saw a significant increase to $10.5 million in Q2 2003 from $5.6 million in Q2 2002, largely due to the upfront payment and shared development costs related to the IL-1 Trap.

What is the company's financial health and cash position?

Regeneron's cash and cash equivalents stood at $129.7 million as of June 30, 2003, an increase from $80.1 million at the end of 2002. This improvement is partly due to the $27 million upfront payment and $48 million equity investment from Novartis. Despite this, the company continues to operate at a net loss, with $28.7 million in Q2 2003, indicating a significant burn rate that is being managed through its cash reserves and financing activities.

What are the key updates on Regeneron's drug development pipeline?

The company highlighted progress with AXOKINE, which showed statistically significant weight loss in Phase III trials, though antibody development limited average weight loss. A Phase II trial in type 2 diabetes also demonstrated positive results. For the IL-1 Trap, a Phase II trial in rheumatoid arthritis is progressing, with results anticipated in late 2003. Other pipeline candidates like VEGF Trap and IL-4/13 Trap are in earlier stages of development.

Are there any significant risks or litigation facing the company?

Regeneron is facing securities class action lawsuits alleging misstatements regarding the safety and efficacy of AXOKINE. The company believes these lawsuits are without merit. Additionally, a significant risk inherent in its business is the potential for clinical trial failures, the development of antibodies to its protein-based therapeutics, and challenges in obtaining regulatory approvals, all of which could materially impact future operating results.

REGN 10-Q Quarterly Report Q2 FY2003 — Revenue, Net Income, EPS

Summary

Regeneron Pharmaceuticals, Inc. (REGN) reported its second quarter 2003 financial results, showing increased revenues primarily driven by a significant contribution from its collaboration with Novartis for the IL-1 Trap. Despite revenue growth, the company continued to incur substantial net losses, consistent with its ongoing investment in research and development for its pipeline of product candidates. The company's cash position remains strong, bolstered by the upfront payment and equity investment from Novartis, providing runway for continued operations. Key development updates include promising, though limited, Phase III results for AXOKINE in obesity, alongside ongoing Phase II trials. Progress is also being made in the Phase II trial for the IL-1 Trap, with results anticipated in the latter half of 2003. Management is focused on advancing its diverse pipeline, which includes candidates for obesity, inflammatory diseases, and cancer, while managing financial resources to support these efforts. Investors should monitor the clinical trial progress, partnership developments, and the company's cash burn rate.

Key Highlights

1Total revenue increased to $10.5 million for Q2 2003 from $5.6 million in Q2 2002, driven by the Novartis collaboration on the IL-1 Trap.
2Research and development (R&D) expenses increased to $33.7 million in Q2 2003 from $30.7 million in Q2 2002, reflecting continued investment in clinical programs.
3Net loss for Q2 2003 was $28.7 million ($0.58 per share), a slight improvement from a net loss of $30.4 million ($0.69 per share) in Q2 2002.
4The company ended the quarter with $129.7 million in cash and cash equivalents, an increase from $80.1 million at the end of 2002, supported by the Novartis collaboration.
5AXOKINE Phase III trial showed statistically significant weight loss but was limited by antibody development; Phase II trial in type 2 diabetes also showed weight loss.
6The IL-1 Trap Phase II trial for rheumatoid arthritis is ongoing with results expected in the second half of 2003.
7Regeneron has $200 million in convertible notes outstanding, maturing in 2008, with a 5.5% annual interest rate.

REGENERON PHARMACEUTICALS, INC. Quarterly Report for Q2 Ended Jun 30, 2003

Summary

Key Highlights

Frequently Asked Questions